Oxular is developing disruptive treatments for retinal diseases. Oxular’s sustained-release formulations are engineered to last up to one year following single administration and perform in specific small spaces in the eye.

Biotechnology

Oxular

Thomas Cavanagh

Paul Pritchard

Stacey Tucker

Ronald Yamamoto

Rafiq Hasan

Dina Chaya

Dmitrij Hristodorov

Geert-Jan Mulder

Christina Takke

The Business Development Team at Oxular is responsible for identifying and nurturing strategic partnerships, exploring new market opportunities, and driving the commercialization of innovative retinal disease treatments. This team collaborates closely with cross-functional departments to align business strategies with product development, ensuring that Oxular's sustained-release formulations effectively reach the market and deliver transformative patient outcomes.

Business Development Team

The Leadership Team at Oxular drives the strategic vision and operational execution of the company’s innovative therapies for retinal diseases. Comprising experts in medicine, science, and business, the team collaborates to ensure the development of effective sustained-release formulations, guiding research initiatives and regulatory compliance while fostering partnerships to maximize the impact of their groundbreaking treatments.

Leadership Team

The Clinical Operations Team at Oxular is responsible for overseeing the planning, execution, and management of clinical trials for retinal disease treatments. This team collaborates closely with regulatory affairs to ensure compliance, coordinates with cross-functional teams to optimize trial efficiency, and focuses on delivering data that supports the safety and efficacy of Oxular's innovative sustained-release formulations.

Oxular

Org chart

Board & advisors

Teams

Business Development Team

Leadership Team

Clinical Operations Team

Offices

Oxular

Org chart

Board & advisors

Teams

Business Development Team

Leadership Team

Clinical Operations Team

Offices

Related companies